Hide metadata

dc.contributor.authorRolová, Gabriela
dc.contributor.authorEide, Desiree
dc.contributor.authorGabrhelík, Roman
dc.contributor.authorOdsbu, Ingvild
dc.contributor.authorClausen, Thomas
dc.contributor.authorSkurtveit, Svetlana
dc.date.accessioned2023-08-01T05:03:10Z
dc.date.available2023-08-01T05:03:10Z
dc.date.issued2023
dc.identifier.citationSubstance Abuse Treatment, Prevention, and Policy. 2023 Jul 28;18(1):47
dc.identifier.urihttp://hdl.handle.net/10852/102850
dc.description.abstractBackground Physical diseases represent a significant burden for opioid agonist treatment (OAT) patients. This study described physical morbidity in two national cohorts of OAT patients focusing on gender differences. Methods This population-based cohort study linking multiple health registers investigated physical diseases (ICD-10) in patients receiving OAT in the Czech Republic (N = 4,280) and Norway (N = 11,389) during 2010–2019. Gender-stratified analysis was performed. Results Overall, we found a large burden of physical morbidity across gender groups in OAT patients. In the Czech Republic and Norway, women in OAT had a significantly higher prevalence of physical diseases across most diagnostic chapters, notably genitourinary diseases and neoplasms. Injuries/external causes and infectious/parasitic diseases were among the most common diseases in both women and men. Viral hepatitis accounted for over half of infectious morbidity in women and men in both cohorts. Conclusions Our findings support the need for early screening, detection, and treatment of diseases and conditions across organ systems and the integration of health promotion activities to reduce physical morbidity in OAT patients. The gender differences underline the need for a tailored approach to address specific medical conditions.
dc.language.isoeng
dc.rightsThe Author(s); licensee BioMed Central Ltd.
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleGender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway
dc.typeJournal article
dc.date.updated2023-08-01T05:03:11Z
dc.creator.authorRolová, Gabriela
dc.creator.authorEide, Desiree
dc.creator.authorGabrhelík, Roman
dc.creator.authorOdsbu, Ingvild
dc.creator.authorClausen, Thomas
dc.creator.authorSkurtveit, Svetlana
dc.identifier.cristin2165162
dc.identifier.doihttps://doi.org/10.1186/s13011-023-00557-8
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.type.versionPublishedVersion
cristin.articleid47


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International